Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
about
A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literatureA Six-Stage Workflow for Robust Application of Systems Pharmacology.Multiscale Modeling in the Clinic: Drug Design and DevelopmentModel-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.
P2860
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@ast
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@en
type
label
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@ast
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@en
prefLabel
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@ast
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@en
P2093
P2860
P356
P1476
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
@en
P2093
P2860
P356
10.1038/PSP.2014.14
P577
2014-05-21T00:00:00Z